Event Monitoring System to Classify Unexpected Events for Production Planning

[EN] Production planning prepares companies to a future production scenario. The decision process followed to obtain the production plan considers real data and estimated data of this future scenario. However, these plans can be affected by unexpected events that alter the planned scenario and in consequence, the production planning. This is especially critical when the production planning is ongoing. Thus providing information about these events can be critical to reconsider the production planning. We herein propose an event monitoring system to identify events and to classify them into different impact levels. The information obtained from this system helps to build a risk matrix, which determines the significance of the risk from the impact level and the likelihood. A prototype has been built following this proposal.This research has been carried out in the framework of the project GV/2014/010 funded by the Generalitat Valenciana (Identificacion de la informacion proporcionada por los nuevos sistemas de deteccion accesibles mediante internet en el ambito de las "sensing enterprises" para la mejora de la toma de decisiones en la planificacion de la produccion).Boza, A.; Alarcón Valero, F.; Alemany Díaz, MDM.; Cuenca, L. (2017). Event Monitoring System to Classify Unexpected Events for Production Planning. Lecture Notes in Business Information Processing. 291:140-154. https://doi.org/10.1007/978-3-319-62386-3_7S140154291Barták, R.: On the boundary of planning and scheduling: a study (1999)Buzacott, J.A., Corsten, H., Gössinger, R., Schneider, H.M.: Production Planning and Control: Basics and Concepts. Oldenbourg Wissenschaftsverlag, München (2012)Özdamar, L., Bozyel, M.A., Birbil, S.I.: A hierarchical decision support system for production planning (with case study). Eur. J. Oper. Res. 104(3), 403–422 (1998)Van Wezel, W., Van Donk, D.P., Gaalman, G.: The planning flexibility bottleneck in food processing industries. J. Oper. Manag. 24(3), 287–300 (2006)Shamsuzzoha, A.H., Rintala, S., Cunha, P.F., Ferreira, P.S., Kankaanpää, T., Maia Carneiro, L.: Event monitoring and management process in a non-hierarchical business network. In: Intelligent Non-hierarchical Manufacturing Networks, pp. 349–374. Wiley, Hoboken (2013)Sacala, I.S., Moisescu, M.A., Repta, D.: Towards the development of the future internet based enterprise in the context of cyber-physical systems. In: 19th International Conference on Control Systems and Computer Science, CSCS 2013, pp. 405–412 (2013)Chen, K.C.: Decision support system for tourism development: system dynamics approach. J. Comput. Inf. Syst. 45(1), 104–112 (2004)Boza, A., Alemany, M.M.E., Vicens, E., Cuenca, L.: Event management in decision-making processes with decision support systems. In: 5th International Conference on Computers Communications and Control (2014)Liao, S.-H.: Expert system methodologies and applications–a decade review from 1995 to 2004. Expert Syst. Appl. 28(1), 93–103 (2005)ISO: 73: 2009: Risk management vocabulary. International Organization for Standardization (2009)Chan, F.T.S., Au, K.C., Chan, P.L.Y.: A decision support system for production scheduling in an ion plating cell. Expert Syst. Appl. 30(4), 727–738 (2006)Weinstein, L., Chung, C.-H.: Integrating maintenance and production decisions in a hierarchical production planning environment. Comput. Oper. Res. 26(10–11), 1059–1074 (1999)Poon, T.C., Choy, K.L., Chan, F.T.S., Lau, H.C.W.: A real-time production operations decision support system for solving stochastic production material demand problems. Expert Syst. Appl. 38(5), 4829–4838 (2011)SAP AG: SAP AG 2014. Next-Generation Business and the Internet of Things. Studio SAP | 27484enUS (14/03) (2014)Carneiro, L.M., Cunha, P., Ferreira, P.S., Shamsuzzoha, A.: Conceptual framework for non-hierarchical business networks for complex products design and manufacturing. Procedia CIRP 7, 61–66 (2013)Vargas, A., Cuenca, L., Boza, A., Sacala, I., Moisescu, M.: Towards the development of the framework for inter sensing enterprise architecture. J. Intell. Manuf. 26, 55–72 (2016)Barash, G., Bartolini, C., Wu, L.: Measuring and improving the performance of an IT support organization in managing service incidents, pp. 11–18 (2007)Liu, R., Kumar, A., van der Aalst, W.: A formal modeling approach for supply chain event management. Decis. Support Syst. 43(3), 761–778 (2007)Söderholm, A.: Project management of unexpected events. Int. J. Proj. Manag. 26(1), 80–86 (2008)Bearzotti, L.A., Salomone, E., Chiotti, O.J.: An autonomous multi-agent approach to supply chain event management. Int. J. Prod. Econ. 135(1), 468–478 (2012)Baron, M.M., Pate-Cornell, M.E.: Designing risk-management strategies for critical engineering systems. IEEE Trans. Eng. Manag. 46(1), 87–100 (1999)Bartolini, C., Stefanelli, C., Tortonesi, M.: SYMIAN: analysis and performance improvement of the IT incident management process. IEEE Trans. Netw. Serv. Manag. 7(3), 132–144 (2010)Cox Jr., L.A.: What’s wrong with risk matrices? Risk Anal. Int. J. 28(2), 497–512 (2008)Shim, J.P., Warkentin, M., Courtney, J.F., Power, D.J., Sharda, R., Carlsson, C.: Past, present, and future of decision support technology. Decis. Support Syst. 33(2), 111–126 (2002)Steiger, D.M.: Enhancing user understanding in a decision support system: a theoretical basis and framework (2015). http://dx.doi.org/10.1080/07421222.1998.11518214Turban, E., Aronson, J., Liang, T.-P.: Decision Support Systems and Intelligent Systems, 7th edn. Pearson Prentice Hall, Upper Saddle River (2005)Turban, E., Watkins, P.R.: Integrating expert systems and decision support systems, 10, 121–136 (1986)Cohen, D., Asín, E.: Sistemas de información para los negocios: un enfoque de toma de decisiones. McGraw-Hill, New York City (2001)Boza, A., Cortés, B., Alemany, M.M.E., Vicens, E.: Event monitoring software application for production planning systems. In: Cortés, P., Maeso-González, E., Escudero-Santana, A. (eds.) Enhancing Synergies in a Collaborative Environment. Springer, Heidelberg (2015). doi: 10.1007/978-3-319-14078-0_14Boza, A., Alarcón, F., Alemany, M.M.E., Cuenca, L.: Event classification system to reconsider the production planning. In: Proceedings of the 18th International Conference on Enterprise Information Systems, pp. 82–88 (2016)Maximal Software: What is MPL? (2016). http://www.maximalsoftware.com/mpl/what.htm

Migraine attacks the Basal Ganglia

<p>Abstract</p> <p>Background</p> <p>With time, episodes of migraine headache afflict patients with increased frequency, longer duration and more intense pain. While episodic migraine may be defined as 1-14 attacks per month, there are no clear-cut phases defined, and those patients with low frequency may progress to high frequency episodic migraine and the latter may progress into chronic daily headache (> 15 attacks per month). The pathophysiology of this progression is completely unknown. Attempting to unravel this phenomenon, we used high field (human) brain imaging to compare functional responses, functional connectivity and brain morphology in patients whose migraine episodes did not progress (LF) to a matched (gender, age, age of onset and type of medication) group of patients whose migraine episodes progressed (HF).</p> <p>Results</p> <p>In comparison to LF patients, responses to pain in HF patients were significantly lower in the caudate, putamen and pallidum. Paradoxically, associated with these lower responses in HF patients, gray matter volume of the right and left caudate nuclei were significantly larger than in the LF patients. Functional connectivity analysis revealed additional differences between the two groups in regard to response to pain.</p> <p>Conclusions</p> <p>Supported by current understanding of basal ganglia role in pain processing, the findings suggest a significant role of the basal ganglia in the pathophysiology of the episodic migraine.</p

Gene Expression Changes in the Motor Cortex Mediating Motor Skill Learning

The primary motor cortex (M1) supports motor skill learning, yet little is known about the genes that contribute to motor cortical plasticity. Such knowledge could identify candidate molecules whose targeting might enable a new understanding of motor cortical functions, and provide new drug targets for the treatment of diseases which impair motor function, such as ischemic stroke. Here, we assess changes in the motor-cortical transcriptome across different stages of motor skill acquisition. Adult rats were trained on a gradually acquired appetitive reach and grasp task that required different strategies for successful pellet retrieval, or a sham version of the task in which the rats received pellet reward without needing to develop the reach and grasp skill. Tissue was harvested from the forelimb motor-cortical area either before training commenced, prior to the initial rise in task performance, or at peak performance. Differential classes of gene expression were observed at the time point immediately preceding motor task improvement. Functional clustering revealed that gene expression changes were related to the synapse, development, intracellular signaling, and the fibroblast growth factor (FGF) family, with many modulated genes known to regulate synaptic plasticity, synaptogenesis, and cytoskeletal dynamics. The modulated expression of synaptic genes likely reflects ongoing network reorganization from commencement of training till the point of task improvement, suggesting that motor performance improves only after sufficient modifications in the cortical circuitry have accumulated. The regulated FGF-related genes may together contribute to M1 remodeling through their roles in synaptic growth and maturation.McGovern Institute for Brain Research at MITNational Institutes of Health (U.S.) ((NIH grant 1-RC1-NS068103-01)National Institutes of Health (U.S.) (NIH grant R01-MH084966)Roberto Rocca Education Program (Fellowship)Massachusetts Institute of Technology. Undergraduate Research Opportunities Program (Fellowship)Italy. Ministero dell'istruzione, dell'università e della ricerca (MIUR grant RBIN04H5AS)Italy. Ministero dell'istruzione, dell'università e della ricerca (MIUR grant RBLA03FLJC)Italy. Ministero dell'istruzione, dell'università e della ricerca (FIRB n. RBAP10L8TY

Search for new phenomena in final states with an energetic jet and large missing transverse momentum in pp collisions at √ s = 8 TeV with the ATLAS detector

Results of a search for new phenomena in final states with an energetic jet and large missing transverse momentum are reported. The search uses 20.3 fb−1 of √ s = 8 TeV data collected in 2012 with the ATLAS detector at the LHC. Events are required to have at least one jet with pT > 120 GeV and no leptons. Nine signal regions are considered with increasing missing transverse momentum requirements between Emiss T > 150 GeV and Emiss T > 700 GeV. Good agreement is observed between the number of events in data and Standard Model expectations. The results are translated into exclusion limits on models with either large extra spatial dimensions, pair production of weakly interacting dark matter candidates, or production of very light gravitinos in a gauge-mediated supersymmetric model. In addition, limits on the production of an invisibly decaying Higgs-like boson leading to similar topologies in the final state are presente

The politics of vibrant matter: consistency, containment and the concrete of Mussolini’s bunker

This article explores the idea of how vibrancy can be produced. Specifically, the attempt is to investigate the multiplicities of vibrancy by considering one of Mussolini’s bunkers. The author examines the location of the bunker in the EUR (Esposizione Universale Romana) neighbourhood in Rome, the bunker’s materiality, and the context and social meaning of the bunker through a contemporary art exhibition called ‘Confronti’ (Confrontations) that took place in the bunker in 2009. The article argues that while emphasizing matter’s inherent vibrancy may be useful in some cases, there is also merit in further unpacking the ways in which vibrancy is produced. In this example, the concrete bunker expresses vibrancy through the processes involved in the emergent material form, and in the sustained politics and social considerations embedded in valuing tangible urban heritage

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

In this phase II, multicentre trial, patients with metastatic breast cancer (MBC) were treated with a combination of gemcitabine, epirubicin and paclitaxel (GET). The primary objective of this study was to determine the tolerability and activity in terms of complete responce (CR) and overall response rate of the GET combination in this patient population. Patients with no prior treatment for MBC, and at least one bidimensionally measurable lesion received gemcitabine 1000 mg m(-2) intravenously (i.v.) over 30 min on days 1 and 4, followed by epirubicin i.v. at 90 mg m(-2) on day 1, and paclitaxel 175 mg m(-2) over 3 h on day 1, every 21 days, up to eight courses. From May 1999 to June 2000, 48 patients were enrolled from seven Italian institutions. A total of 297 chemotherapy courses were administered with a median of six cycles patient(-1) (range 1-8). Seven patients (15%) obtained CR and 27 patients (56%) had partial responce, for an overall response rate of 71% (95%; CI: 58.3-83.7). After a median follow-up of 23.7 months (range 7.0-34.4), median progression-free survival was 10.5 months (95%; CI: 9.2-11.7), and median overall survival 25.9 months. The main haematological toxicity consisted of grade 3 or 4 neutropenia that occurred in 62% of cycles (22% grade 4 and 40% grade 3). The GET combination is active and well tolerated as first-line chemotherapy for MBC

Transcriptome Analysis of Neisseria meningitidis in Human Whole Blood and Mutagenesis Studies Identify Virulence Factors Involved in Blood Survival

During infection Neisseria meningitidis (Nm) encounters multiple environments within the host, which makes rapid adaptation a crucial factor for meningococcal survival. Despite the importance of invasion into the bloodstream in the meningococcal disease process, little is known about how Nm adapts to permit survival and growth in blood. To address this, we performed a time-course transcriptome analysis using an ex vivo model of human whole blood infection. We observed that Nm alters the expression of ≈30% of ORFs of the genome and major dynamic changes were observed in the expression of transcriptional regulators, transport and binding proteins, energy metabolism, and surface-exposed virulence factors. In particular, we found that the gene encoding the regulator Fur, as well as all genes encoding iron uptake systems, were significantly up-regulated. Analysis of regulated genes encoding for surface-exposed proteins involved in Nm pathogenesis allowed us to better understand mechanisms used to circumvent host defenses. During blood infection, Nm activates genes encoding for the factor H binding proteins, fHbp and NspA, genes encoding for detoxifying enzymes such as SodC, Kat and AniA, as well as several less characterized surface-exposed proteins that might have a role in blood survival. Through mutagenesis studies of a subset of up-regulated genes we were able to identify new proteins important for survival in human blood and also to identify additional roles of previously known virulence factors in aiding survival in blood. Nm mutant strains lacking the genes encoding the hypothetical protein NMB1483 and the surface-exposed proteins NalP, Mip and NspA, the Fur regulator, the transferrin binding protein TbpB, and the L-lactate permease LctP were sensitive to killing by human blood. This increased knowledge of how Nm responds to adaptation in blood could also be helpful to develop diagnostic and therapeutic strategies to control the devastating disease cause by this microorganism

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the epidermal growth factor receptor (EGFR). Preclinical data suggested that HER3 overexpression increases sensitivity to TKIs. A total of 82 NSCLC patients treated with gefitinib (250 mg), and previously evaluated for EGFR and HER2 status by fluorescence in situ hybridisation (FISH) and DNA sequencing, and for Phospho-Akt status by immunohistochemistry, were investigated for HER3 genomic gain by FISH. Patients with high polysomy and gene amplification were considered as HER3 FISH positive (+). HER3 FISH+ pattern was significantly associated with female gender (P=0.02) and never smoking history (P=0.02). Patients with HER3+ tumours (26.8%) had a significantly longer time to progression (3.7 vs 2.7, P=0.04) than patients with HER3− tumours, but not a significantly better response rate or survival. Patients with EGFR+/HER3+ tumours had higher objective response rate (36.4 vs 9.9%, P=0.03) and time to progression (7.7 vs 2.7 months, P=0.03) than patients with EGFR− and/or HER3− tumours, but no significantly longer survival. No difference in response was observed according to HER3 status in patients with EGFR+ tumours. Patients with HER2+/HER3+ tumours had similar outcome as patients with HER2− and/or HER3− tumours. Significantly different clinical end points were not observed between patients with HER3+/P-Akt+ and HER3− and/or P-Akt− tumours. Genomic gain for HER3 is not a marker for response or resistance to TKI therapy in advanced NSCLC patients

Automated High-Content Live Animal Drug Screening Using C. elegans Expressing the Aggregation Prone Serpin α1-antitrypsin Z

The development of preclinical models amenable to live animal bioactive compound screening is an attractive approach to discovering effective pharmacological therapies for disorders caused by misfolded and aggregation-prone proteins. In general, however, live animal drug screening is labor and resource intensive, and has been hampered by the lack of robust assay designs and high throughput work-flows. Based on their small size, tissue transparency and ease of cultivation, the use of C. elegans should obviate many of the technical impediments associated with live animal drug screening. Moreover, their genetic tractability and accomplished record for providing insights into the molecular and cellular basis of human disease, should make C. elegans an ideal model system for in vivo drug discovery campaigns. The goal of this study was to determine whether C. elegans could be adapted to high-throughput and high-content drug screening strategies analogous to those developed for cell-based systems. Using transgenic animals expressing fluorescently-tagged proteins, we first developed a high-quality, high-throughput work-flow utilizing an automated fluorescence microscopy platform with integrated image acquisition and data analysis modules to qualitatively assess different biological processes including, growth, tissue development, cell viability and autophagy. We next adapted this technology to conduct a small molecule screen and identified compounds that altered the intracellular accumulation of the human aggregation prone mutant that causes liver disease in α1-antitrypsin deficiency. This study provides powerful validation for advancement in preclinical drug discovery campaigns by screening live C. elegans modeling α1-antitrypsin deficiency and other complex disease phenotypes on high-content imaging platforms